The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•24 February 2026•

1 min read

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT Cancer Treatment

Key Facts

1Japan's Ministry of Health, Labour and Welfare (MHLW) granted marketing approval for Alpha DaRT for treating locally advanced or recurrent head and neck cancer.

Alpha Tau Medical Ltd. (Nasdaq: DRTS) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted marketing approval for its Alpha DaRT technology. The approval specifically covers the treatment of locally advanced or recurrent head and neck cancer that is unresectable. This milestone represents the first clinical authorization for the company's alpha-emitting radiotherapeutic technology outside of Israel. As part of the commercial rollout, the company plans to initiate a post-market surveillance program within the Japanese market. The regulatory green light is expected to significantly bolster the company's global commercialization strategy and open a substantial new revenue stream. Investors view this development as a major fundamental catalyst for the biotech firm, validating its technology in a major global market.